Patents by Inventor Douglas S. Jones, II

Douglas S. Jones, II has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEPATOCYTE GROWTH FACTOR FRAGMENTS THAT FUNCTION AS POTENT MET RECEPTOR AGONISTS AND ANTAGONISTS
    Publication number: 20220033453
    Abstract: The NK1 fragment of hepatocyte growth factor (HGF) binds to and activates the Met receptor, a transmembrane receptor tyrosine kinase that plays a critical role in embryonic development and organ formation. The instant application discloses NK1 variant polypeptides which act as agonists or antagonists of HGF. Further disclosed are covalently linked NK1 variant polypeptides. Many of the disclosed variant polypeptides possess improved stability characteristics.
    Type: Application
    Filed: March 22, 2021
    Publication date: February 3, 2022
    Inventors: Jennifer R. Cochran, Douglas S. Jones, II, Ping-Chuan Tsai
  • Hepatocyte Growth Factor Fragments that Function as Potent Met Receptor Agonists and Antagonists
    Publication number: 20170305985
    Abstract: The NK1 fragment of hepatocyte growth factor (HGF) binds to and activates the Met receptor, a transmembrane receptor tyrosine kinase that plays a critical role in embryonic development and organ formation. The instant application discloses NK1 variant polypeptides which act as agonists or antagonists of HGF. Further disclosed are covalently linked NK1 variant polypeptides. Many of the disclosed variant polypeptides possess improved stability characteristics.
    Type: Application
    Filed: November 30, 2016
    Publication date: October 26, 2017
    Inventors: Jennifer R. COCHRAN, Douglas S. JONES II, Ping-Chuan TSAI
  • Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
    Patent number: 9556248
    Abstract: The NK1 fragment of hepatocyte growth factor (HGF) binds to and activates the Met receptor, a transmembrane receptor tyrosine kinase that plays a critical role in embryonic development and organ formation. The instant application discloses NK1 variant polypeptides which act as agonists or antagonists of HGF. Further disclosed are covalently linked NK1 variant polypeptides. Many of the disclosed variant polypeptides possess improved stability characteristics.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: January 31, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jennifer R. Cochran, Douglas S. Jones, II, Ping-Chuan Tsai
  • HEPATOCYTE GROWTH FACTOR FRAGMENTS THAT FUNCTION AS POTENT MET RECEPTOR AGONISTS AND ANTAGONISTS
    Publication number: 20130171068
    Abstract: The NK1 fragment of hepatocyte growth factor (HGF) binds to and activates the Met receptor, a transmembrane receptor tyrosine kinase that plays a critical role in embryonic development and organ formation. The instant application discloses NK1 variant polypeptides which act as agonists or antagonists of HGF. Further disclosed are covalently linked NK1 variant polypeptides. Many of the disclosed variant polypeptides possess improved stability characteristics.
    Type: Application
    Filed: March 21, 2011
    Publication date: July 4, 2013
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jennifer R. Cochran, Douglas S. Jones, II, Ping-Chuan Tsai